Poxel Income Statement | StatInvestor

Health Care & Life Sciences » Biotechnology | Poxel

Poxel S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.

2013

2014

2015

2016

2017

2018

Sales/Revenue

59.70

70.30

5,290.10

74,605

Cost of Goods Sold (COGS) incl. D&A

15.40

12.30

Gross Income

15.40

12.30

SG&A Expense

10,189.60

8,855.50

13,666.40

27,500.40

30,276.60

65,557

EBIT

10,205.00

8,867.90

13,629.80

27,439.00

25,024.40

8,986

Unusual Expense

13,263.30

6,858.10

124.20

Non Operating Income/Expense

23.80

1.20

28.70

17.30

378.80

724

Interest Expense

30.60

406.80

918.80

572.40

80.60

Pretax Income

23,365.80

16,059.60

14,159.10

27,707.00

25,420.30

10,050

Income Tax

2,913.10

1,977.10

1,918.10

3,224.10

3,122.20

3,475

Consolidated Net Income

20,452.70

14,082.40

12,241.00

24,482.90

22,298.10

13,525

Net Income

20,452.70

14,082.40

12,241.00

24,482.90

22,298.10

13,525

Net Income After Extraordinaries

20,452.70

14,082.40

12,241.00

24,482.90

22,298.10

13,525

Net Income Available to Common

20,452.70

14,082.40

12,241.00

24,482.90

22,298.10

13,525

EPS (Basic)

5.45

3.76

0.68

1.16

0.97

0.54

Basic Shares Outstanding

3,750.00

17,918.90

21,066.80

23,033.30

24,833.30

EPS (Diluted)

5.45

3.76

0.68

1.16

0.97

0.53

Diluted Shares Outstanding

3,750.00

17,918.90

21,066.80

23,033.30

25,518.90

EBITDA

10,189.60

8,855.50

13,606.80

27,407.00

24,986.50

9,048

Other Operating Expense

23.20

Non-Operating Interest Income

109.30

71.90

293.90

287.10

63.50

368

About Poxel

View Profile

Address	259/261, avenue Jean Jaurès Lyon Rhone-Alpes 69007 France
Employees	-
Website	http://www.poxel.com
Updated	07/08/2019
Poxel SA is a pharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, and PXL770. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.